Norwich, NY -- (ReleaseWire) -- 07/07/2009 -- Norwich Pharmaceuticals, Inc., a perennial industry leader in contract manufacturing and packaging, has announced the formation of a strategic alliance with Emerson Resources, Inc.

According to Chris Calhoun, president of Norwich Pharmaceuticals, the arrangement formally brings together the capabilities of the two companies in a complementary fashion, enabling both to provide a stronger set of total services to the industry. "This alliance builds on our long-standing relationship with Emerson, and on our new full-service capabilities here at Norwich," said Calhoun, "offering a clear path to commercialization for the clients of both our companies."

Adolfo Gomez, president of Emerson Resources, emphasized the importance of that long-standing relationship. "Our two companies were formed at about the same time, we've grown together, and we've been working together for years," said Gomez. "Being relatively close to one another, we have been able to quickly access and share each other's resources."

Gomez went on to point out the benefits of the synergistic relationship that has now been formally established between the two companies. "Ours has always been a relationship of synergy," says Gomez, "providing our clients with added value through the efficiencies of collaboration. By leveraging our collective experience and combined production capacity, both companies can bring faster, more flexible full-service capabilities to our customers, without the burdens of added bureaucracy that often hamper our competitors."

The management of both companies see this alliance as a perfect union of technologies and focus, with no competitive conflicts to hamper cooperation. "We each have our areas of strength, and our synergy of equipment and capabilities make our collaborations seamless," said Calhoun. "It is an alliance of opportunity, not of necessity. When two strong companies come together under these circumstances, everybody wins."

Norwich, which has served the pharmaceutical industry for over 100 years, recently completed a multi-million dollar expansion of its core capabilities and services, placing a new focus on full product lifecycle support, with a concentration in the area of new product development. Prior to this expansion, New York-based Norwich limited its scope of services to commercial manufacturing and packaging.

According to analysts, the company's expansion into new product development indicates the aggressiveness with which Norwich is approaching its place in the future of outsource services. With the company's selective build-up of personnel, skills and major capital investments, Norwich is intent on increasing its role in the future of biopharmaceutical development as more and more manufacturers seek state-of-the-art outsource services.

Emerson Resources, Inc. based in Norristown, Pennsylvania, was formed from the merger of three technology companies, and is known for its proven track record of delivering industry-leading research, product development, technical services, and technical training. The company's principal services include API characterization, pre-formulation and excipient compatibility studies, analytical method development and validation, formulation development, stability studies, Phase 1 and 2 clinical trial material manufacturing, process development, engineering, and validation.

Based on the statements of both management teams, the alliance between the two companies will be overseen by a joint governance team responsible for overall performance management, and by individual project teams responsible for executing work on individual initiatives. Joint projects will be managed through a single point of contact in order to facilitate speed of execution, ensure the seamless sharing of resources, and to make communication between customers and project coordinators as effortless as possible.

Emerson is expected to take the lead in early stage development and clinical trial material manufacturing. Emerson personnel and expertise will also be frequently called upon in the area of analytical services, especially in support of formulation development, method qualification in support of pilot clinical trials and analytical method transfer.

When it comes to the transfer of pilot clinical trial manufacturing from formulation to production, flexibility and speed will be key components of our success giving our clients access to both Norwich and Emerson facilities. Pivotal (Phase III) and commercial batches will be manufactured exclusively at the Norwich facility with full regulatory support for compiling INDs/ NDA's/ ANDA's and marketing applications for selected projects.

Calhoun emphasized the fact that, simply by combining resources, each company now has a broader range of services to offer its clients. "In addition, this alliance between our two companies provides strong assurances to our clients that we will be able to meet their needs, even in periods of peak demand." said Calhoun. "We look forward to drawing on each other's strengths, tapping into each other's resources, and building a base of confidence that the entire pharmaceutical industry can depend on for many years to come."

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc., based in Norwich, NY, provides comprehensive support services to the pharmaceutical industry on an outsourcing basis – from clinical trial, through scale-up, to commercial launch. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information contact Chris Calhoun, President of Norwich Pharmaceuticals, at chris.calhoun@norwichpharma.com or call 888-674-7979.

About Emerson Resources, Inc.
Emerson Resources, Inc., based in Norristown, PA, provides pharmaceutical development services including, pre-formulation, formulation development, analytical development/validation, stability testing and clinical supplies manufacturing.

For more information contact Aaron Barkley, Business and Strategy Development, abarkley@emersonresources.com or call 610-279-7450 x 228.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Norwich, NY -- (ReleaseWire) -- 06/23/2009 -- Norwich Pharmaceuticals, Inc., an industry leader in contract manufacturing and packaging, has recently completed a major capital investment in infrastructure, controls and the specialized equipment necessary to support the pilot scale formulation and Clinical Trial Material (CTM) manufacture of new and existing pharmaceutical products.

The addition of these small-scale services is a major expansion on the part of the New York-based company, which has served the pharmaceutical industry for over 100 years. Prior to this investment in new product formulation, Norwich concentrated its scope of services in commercial-scale manufacturing and packaging. The company's expansion into new product development required the investment into their pilot-scale equipment and facilities, and signals the aggressiveness with which Norwich is approaching its role in the future of outsourcing services.

As Norwich president, Chris Calhoun indicated, "Small scale development studies require a broad range of equipment." stated Calhoun. "We invested in new, state-of-the-art particle sizing equipment, tablet compression equipment, high shear granulation, fluid bed and mixers with capacities in line with the requirements of formulation activities."

"Our engineers have been diligently comparing the specifications of equipment", said Calhoun, "making certain that what we were putting in place could be scalable and adaptable to meet the varied requirements of several pilot programs at one time."

In addition to the capital investment in equipment and physical infrastructure, Norwich has been attracting top-level industry executives and project management personnel to advance its role in new product development. "We've put together an exceptional technical team," said Calhoun. "We're now in a position to help plan and launch more new initiatives, and then assist our clients throughout the life cycle of a successful product."

Through a selective build-up of personnel and major capital investments it appears that Norwich is committed to an increasing its role in the future of biopharmaceutical development as more and more manufacturers seek state-of-the-art, full-service outsourcing capabilities.

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc., based in Norwich, NY, provides comprehensive support services to the pharmaceutical industry on an outsourcing basis – from clinical trial, through scale-up, to commercial launch. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Norwich, NY -- (ReleaseWire) -- 06/10/2009 -- Norwich Pharmaceuticals, Inc., an industry leader in contract manufacturing and packaging, is now offering comprehensive services toward the development of high-potency compounds in solid, semi-solid, and liquid dosage forms.

The addition of high potent compound capabilities is the result of a major capital investment and expansion of services on the part of the New York-based company, which has served the pharmaceutical industry for over 100 years. In the past, Norwich has concentrated its efforts on providing contracted services to manufacturing and packaging services.

Commenting on the newly announced services, Norwich Vice President, Technical & Development Services, Carolyn Gherardi, said the company has invested over $3 million in infrastructure, controls and the specialized equipment necessary to support pilot scale Clinical Trial Material (CTM) for the manufacture of high potent compounds, including fast dissolve and controlled release tablets.

"In addition to the capital investment in physical infrastructure, we've put together an outstanding technical team," said Gherardi. "Our people are capable of manufacturing high potent products in a variety of dosage forms and providing a range of analytical services in-house. And, along with the considerable addition of dedicated equipment, we've also increased our staff of highly-qualified specialists to assure consistent performance and rapid response to potential problems."

The potent compound development facility at Norwich features an HVAC system designed for 20 room air changes per hour, utilizing redundant HEPA filtration to eliminate any possibility of cross-contamination. Separate personnel ingress/egress airlocks, with a separate equipment and materials airlock, provide full containment of compounds. The Norwich facility also has a dedicated control system to monitor and regulate the environmental conditions of every development suite.

The expansion into potent compound development further supports the commitment of Norwich management to increase its role in the future of biopharmaceutical development as more and more manufacturers seek state-of-the-art outsourcing services. "Through a selective build-up of personnel and major capital investments we are now well positioned to assist our customers throughout the entire life cycle of their product, as well as help plan and launch new customer initiatives," says Gherardi.

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc., based in Norwich, NY, provides comprehensive support services to the pharmaceutical industry on an outsourcing basis – from clinical trial, through scale-up, to commercial launch. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Norwich, NY -- (ReleaseWire) -- 04/15/2009 -- Norwich Pharmaceuticals, Inc., a perennial leader in contract manufacturing and packaging, has added two more veterans of the industry to top level positions in order to ensure the successful management of its expanded services. Dan Casey joined the company as its Vice President Business Development, and Dale A. Dyer was named Director of Business Development.

Dan Casey most recently served as general manager and director of sales for Covidien Inc., where he managed their outsourcing and contract manufacturing business. Prior to that, Casey, who has 20-plus years of experience in the pharmaceutical industry, held general manager and site director positions with Mallinckrodt, and served as president of D.M. Graham Laboratories. Casey explained his move to Norwich saying, "Norwich has made an unprecedented commitment to our industry's need for flexibility. This is where I belong at this point in the evolution of our industry and in my career."

According to Chris Calhoun, president of Norwich Pharmaceuticals, "Dan Casey is a visionary with a global perspective and a proven ability to plan, develop and implement programs vital to meet present and future industry demands. In tandem with Dale Dyer, we expect to have a significant influence on the success of our clients well into the future."

Dale Dyer has over 25 years of extensive expertise in marketing and sales of contract manufacturing services and brand and generic pharmaceutical products. "Dale has a demonstrated ability to generate and execute an effective business development strategy from the ground up," noted Calhoun. "She will be vital in helping us make the most of our recent specialized equipment investments." Dyer most recently held senior positions at Covidien, Tyco Healthcare and Mallinckrodt Inc., including serving as marketing and sales manager for Covidien since 1996. Earlier in her career Dyer received several national sales awards and achieved top honors while at Glaxo/SmithKlineBeecham and Stuart Pharmaceuticals. "In the past, Norwich limited its scope of services to manufacturing, packaging, and quality control testing support." noted Dyer. "We will now assist customers throughout the life cycle of a product, as well as help plan and launch new initiatives, from simple line extensions to explorations into new product categories."

Norwich has been steadily gearing up for its current expansion of services with major capital investments in specialized technology and through a selective build-up of key personnel. The company, now serving the pharmaceutical industry for over 100 years, will be actively offering full service product development support from formulation through post-marketing, as well as individual services on an as-needed basis in many specialized areas. "We're currently in a position to cost effectively trial new products for our customers prior to going to full-scale production," says company president Chris Calhoun.

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. is an outsourcing provider based in Norwich, NY providing comprehensive support – from clinical trial, through scale-up, to commercial launch – to the pharmaceutical industry. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

There was a time when becoming closely acquainted with all the services and capabilities of a contract pharmaceutical outsourcing provider was only achievable through a face-to-face meeting or by visiting a manufacturing facility in person, but thanks to Norwich Pharmaceuticals all this can now be experienced online.

Norwich, NY -- (ReleaseWire) -- 02/18/2009 -- There was a time when becoming closely acquainted with all the services and capabilities of a contract pharmaceutical outsourcing provider was only achievable through a face-to-face meeting or by visiting a manufacturing facility in person, but thanks to Norwich Pharmaceuticals all this can now be experienced online at www.norwichpharma.com.

Visitors to the home page of the updated site will first notice the clean, elegant, thoughtfully organized look, a reflection of the company's manufacturing philosophy. "We've succeeded in providing the visitor with a very user-friendly way of discovering all the ways our new capabilities and services can meet their project needs", states Norwich President, Chris Calhoun. In achieving this, Norwich's navigation has been simplified thanks to the use of a drop-down menu bar and accessing information from anywhere on the site is only a couple of mouse clicks away.

"As we continue to grow in ways that provide greater advantages and value it's important that the online experience communicate all of these benefits to our customers", notes Doug Drysdale, Norwich's CEO. The company's service areas are now more comprehensively presented. By clicking on the 'services' area of the menu bar, Norwich capabilities from clinical trial support to manufacturing to regulatory services to distribution are displayed in a clear and concise manner.

A virtual plant tour of the Norwich, N.Y. facility is available via the drop down menu by means of a 32-image "photo carousel". Many areas of the 375,000 square-foot plant can now be visited with a click of a mouse.

For those wishing to contact Norwich, the general inquiry page now features an extended compatibility questionnaire section which custom-tailors content and contact person information.

Anyone planning a visit to the Norwich Plant will now find a custom programmed Google map offering customized driving directions. Those requiring overnight accommodations can access preferred lodging information for area hotels. One can even get one-click weather forecast for the Norwich region provided by The Weather Channel.

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. is an outsourcing provider based in Norwich, NY providing comprehensive support – from clinical trial, through scale-up, to commercial launch – to the pharmaceutical industry. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Names Gherardi to Lead New Business Unit - Adds Shah as Vice President, Research & Development

Norwich, NY -- (ReleaseWire) -- 02/12/2009 -- Norwich Pharmaceuticals, Inc., an industry leader in contract manufacturing and packaging, has announced a comprehensive expansion of services and has named Carolyn A. Gherardi as principal point of contact for those interested in the company's added capabilities.

In addition, the Company has appointed Shailesh B. Shah, MS, RPH to the position of Vice President, Research & Development. Shah, who joins the company from Par Pharmaceuticals, has 25 years of experience developing formulations of both immediate release as well as controlled release solid oral products from concept to market introduction, obtaining three registered US patents for such delivery systems.

Gherardi, who served as VP Operations for the past three years at Norwich, will now hold the title of Vice President, Technology & Development Services (TDS). Prior to joining Norwich in 2001, Gherardi held numerous positions with P&G Pharmaceuticals, covering all phases of the pharmaceutical manufacturing process. A graduate of Clarkson University, Gherardi earned her degree in Chemical Engineering and is a member of the American Institute of Chemical Engineers.

According to Mrs. Gherardi, "As our company motto clearly states, we have always strived to provide our clients with uncommon value and everyday excellence. Through this expansion of our Technology & Development Services, we will be adding substantially to the 'uncommon value' portion of that equation – offering full service product development support from formulation through commercial product optimization, as well as individual services in many specialized areas."

Norwich is currently expanding its development services offerings through a selective build¬up of technical personnel and capital investments in specialized equipment.

In the past, Norwich focused its scope of services primarily on commercial manufacturing and packaging, but have undertaken development and optimization projects for multiple customers. It now plans to apply this experience to assist customers throughout the life cycle of a product, as well as help customers plan and launch new initiatives, from line extensions to explorations into new product categories.

"Clients can come to us for a single specialized service or for a complete end-to-end solution," says Gherardi. "We're ready to take on any technical service request that is made of us, with no long-term or contingency commitment necessary. We'll even help our customers overcome hurdles in their day-to-day operations, from improving their quality control processes to helping them replace inefficient suppliers."

When asked who Norwich will be targeting with its full-service message Gherardi said, "The need for our Technology & Development Services exists in multiple segments of the Pharma industry. Our immediate goal is to communicate the full extent of our expanded services to all Pharmaceutical companies from Big Pharma to Virtual and Specialty Pharma companies. Those who see the greatest value in what we can now do for them, will be the first in line for our services. We expect demand for outsourcing to continue to grow given the downsizing and consolidation of development and manufacturing capacity currently taking place in our industry".

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. is an outsourcing provider based in Norwich, NY providing comprehensive support – from clinical trial, through scale-up, to commercial launch – to the pharmaceutical industry. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Norwich Pharmaceuticals bolsters customer service offerings with SupplyScape’s business process collaboration environment

Norwich, NY and Woburn, MA -- (ReleaseWire) -- 09/16/2008 -- Norwich Pharmaceuticals, Inc., a leading provider of contract manufacturing and packaging services, today announced that it will be implementing SupplyScape Corporation's Nexus solution to drive visibility, control, and efficiency within its business operations and among its trading partners. Norwich will utilize Nexus to offer its diverse client base a full suite of serialization services to monitor and optimize product movement, security and supply chain performance.

SupplyScape Nexus is a business collaboration environment designed to help companies and their trading partners connect and share rich product information across business processes. By combining serialization and electronic pedigree (ePedigree) information with operational and transaction data, organizations can dramatically improve supply chain visibility and business responsiveness to changing supply chain conditions.

As one of the first outsourcing providers to implement the Nexus solution, Norwich Pharmaceuticals president, Chris Calhoun, views this initiative as part and parcel to the company's mission. "Norwich is committed to providing our customers with uncommon value and everyday excellence – and SupplyScape helps us achieve that." Calhoun added, "In addition to innovative technology, deep domain expertise, and strong partnerships with technology leaders such as SAP, SupplyScape's value chain network-based approach enables us to offer our customers a comprehensive set of serialization packaging and patient safety services to meet all their customers' needs."

Mark O'Connell, president and chief executive officer of SupplyScape, commented, "Norwich understands that serializing drug products and linking this serialization information between trading partners creates global business value opportunities that extend far beyond regulatory compliance. The Nexus capabilities for managing, sharing and acting on serialization information and ePedigree data will enable Norwich to strengthen its business operations and offer outsourced value-added visibility and traceability services to its customers and their trading partners that are unmatched in the pharmaceutical industry."

About Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. is an outsourcing provider based in Norwich, NY providing comprehensive support – from clinical trial, through scale-up, to commercial launch – to the pharmaceutical industry. The company brings over 100 years of experience to the manufacture, packaging, associated quality services, and distribution of solid dose, semi-solid, and liquid pharmaceutical products. For more information, visit http://www.norwichpharma.com.

About SupplyScape
SupplyScape Corporation is the leading provider of software to secure the safety and value of the global life sciences supply chain. More than 100 companies across the pharmaceutical value chain rely on SupplyScape to help them prepare for global serialization, ePedigree, and track & trace, and to realize business value from their investments in product security and supply chain visibility. For more information, visit http://www.supplyscape.com/.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm